✨ Medicines Act Notices
NEW ZEALAND GAZETTE
No. 26
Health
Medicines Act 1981
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisional consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name |
|---|---|---|---|
| Nelfinavir mesylate 292.25 mg equivalent to 250 mg nelfinavir | Tablet | Mova Pharmaceutical Corporation, Caguas, Puerto Rico | Viracept |
| Nelfinavir mesylate 58.5 mg/g equivalent to 50 mg/g nelfinavir in 144 g | Powder, oral | Mova Pharmaceutical Corporation, Caguas, Puerto Rico | Viracept |
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 30th day of January 1998.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go930
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name |
|---|---|---|---|
| Testosterone 12.2 mg (delivery 2.5 mg/24 hours) | Transdermal patch | TheraTech Inc., Salt Lake City, Utah, United States of America | Andropatch |
| Dextrose anhydrous 500 mg/mL in 90 mL, 100 mL, 200 mL | Solution, infusion | McGaw Biomed Limited, Point Chevalier, Auckland | Dextrose 50% |
| Iopamidol 40.8% in 50 mL, 100 mL, 200 mL | Injection, solution, bag | Abbott Laboratories, North Chicago, Illinois, United States of America | Iopamidol |
| Iopamidol 61.2% in 50 mL, 75 mL, 100 mL, 150 mL, 200 mL | Injection, solution, bag | Abbott Laboratories, North Chicago, Illinois, United States of America | Iopamidol |
| Iopamidol 75.5% in 50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 175 mL, 200 mL | Injection, solution, bag | Abbott Laboratories, North Chicago, Illinois, United States of America | Iopamidol |
| Permethrin 5% w/w in 30 g | Cream, skin | PSM Holdings Limited, Wiri, Auckland | Lyderm |
| Latanoprost 50 µg/mL in 2.5 mL | Drops, eye | Pharmacia & Upjohn AB., Uppsala, Sweden and Liquid Packaging Inc., Woodstock, Illinois, United States of America | Xalatan |
| Zinc oxide 20% w/w in 41.5 g | Stocking, medicated | Perstorp Pharma, Ideon, Sweden | Zipzoc |
Dated this 30th day of January 1998.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.
go930
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1998, No 26
NZLII —
NZ Gazette 1998, No 26
✨ LLM interpretation of page content
🏥 Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare30 January 1998
Medicines Act, Provisional Consent, Nelfinavir mesylate, Viracept, Mova Pharmaceutical Corporation
- G. R. Boyd, Chief Advisor, Regulation and Safety
🏥 Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare30 January 1998
Medicines Act, Consent to Distribution, Testosterone, Dextrose, Iopamidol, Permethrin, Latanoprost, Zinc oxide, Andropatch, Dextrose 50%, Lyderm, Xalatan, Zipzoc, TheraTech Inc., McGaw Biomed Limited, Abbott Laboratories, PSM Holdings Limited, Pharmacia & Upjohn AB., Perstorp Pharma
- G. R. Boyd, Chief Advisor, Regulation and Safety